Newer approaches are the maintenance of PARP inhibition in patients with germline BRCA mutation in pancreatic adenocarcinoma, and IDH and FGFR inhibition in biliary tract cancer. The gene discussed is PARP1; the disease is pancreatic adenocarcinoma.